Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Databricks, Recursion Pharmaceuticals, and 370+ companies. 5-min read every Tuesday.
Databricks is the world's most valuable data and AI platform — $134B valuation, $4.2B raised. Widely expected to IPO. Track readiness score and timeline.
| Industry | Enterprise Software |
| Stage | Pre-IPO |
| IPO Status | Pre-IPO |
| Valuation | $134B |
| Total Funding | $19B |
| Headquarters | San Francisco, CA |
AI-powered biotech combining biology, chemistry, and machine learning for drug discovery.
| Industry | Biotechnology |
| Stage | Public |
| IPO Status | Public |
| Valuation | $2.5B |
| Total Funding | $939M |
| Headquarters | Salt Lake City, UT |
Databricks is valued at $134B. Recursion Pharmaceuticals is valued at $2.5B. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Databricks has raised $19B. Recursion Pharmaceuticals has raised $939M.
Databricks is currently pre-IPO. Recursion Pharmaceuticals is currently already public. Track both on TechStackIPO for S-1 filings and IPO announcements.
Databricks operates in Enterprise Software, while Recursion Pharmaceuticals operates in Biotechnology.
Databricks is a Enterprise Software company valued at $134B with $19B raised. Recursion Pharmaceuticals is a Biotechnology company valued at $2.5B with $939M raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Databricks and Recursion Pharmaceuticals through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.